Application of polyphyllin II in preparation of drug for enhancing curative effect of cisplatin

The technology of Chonglou saponin and Minshun is applied in the application field of Chonglou saponin II in the preparation of sensitizing cisplatin therapeutic drugs, which can solve the problems of complex action mechanism and the like, and achieve the effects of improving drug resistance and improving antitumor activity.

Pending Publication Date: 2021-11-30
TIANJIN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the mechanism of action of saponin Ⅱ is complex, and it has a good anti-tumor effect and a wide range of anti-tumor activities. However, there is no report on whether the combination of saponin Ⅱ and the conventional chemotherapy drug cisplatin can improve the sensitivity of cisplatin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polyphyllin II in preparation of drug for enhancing curative effect of cisplatin
  • Application of polyphyllin II in preparation of drug for enhancing curative effect of cisplatin
  • Application of polyphyllin II in preparation of drug for enhancing curative effect of cisplatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0012] Pauline saponin Ⅱ, molecular formula is C 51 h 82 o 20 , the molecular weight is 1015.18, white crystalline powder, soluble in organic solvents such as methanol and DMSO, and easily soluble in water; derived from the rhizomes of Liliaceae plants Paris yunnanensis Franch. Purchased from Chengdu Pufeide Biotechnology Co., Ltd., CAS number: 50773-42-7, the structural formula is:

[0013]

[0014] The present invention will be further described below by specific examples.

[0015] Primary anti-tumor activity test method

[0016] 1. Antitumor activity test in vitro

[0017] 1.1 Cell lines and culture

[0018] The small cell lung cancer cell line H446 cell line was purchased from Changsha Youze Biotechnology Co., Ltd., and it was an adherent cell cultured in RPMI1640 medium containing 10% inactivated fetal bovine serum (purchased from Suleibao Company, which contained 100 U / mL penicillin, 100 μg / mL streptomycin), 37°C, 5% CO 2 Cultured in an incubator and saturated ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of polyphyllin II in preparation of a drug for enhancing the curative effect of cisplatin. Research shows that in a lung cancer cell strain H446, only the cell survival rate is slightly reduced when cisplatin is independently used, and the survival rate is greatly reduced after cisplatin is combined with polyphyllin II. Meanwhile, the combined index CI measured by combined application of multiple concentrations of the polyphyllin II and the cisplatin is lower than 1, it is indicated that the polyphyllin II can sensitize the cisplatin and improve the anti-tumor curative effect of the cisplatin. According to the application of polyphyllin II in preparation of the drug for enhancing the curative effect of cisplatin, the traditional Chinese medicine paris polyphylla is wide in source, the detailed in vitro activity test results show that the polyphyllin II extracted and separated from a plant can effectively improve the drug resistance of cisplatin and improve the antitumor activity of the cisplatin when the polyphyllin II is combined with the first-line chemotherapeutic drug cisplatin.

Description

technical field [0001] The invention belongs to the field of cancer chemotherapeutic sensitizing drugs, and relates to a new application of papaya saponin II, that is, the application of paprika saponin II in the preparation of cisplatin-sensitizing curative effect drugs. Background technique [0002] Cisplatin is an indispensable first-line chemotherapy drug for the treatment of lung cancer. It has a unique anti-cancer mechanism and a broad anti-cancer spectrum. It has developed into one of the most widely used chemotherapy drugs for lung cancer. Cisplatin is a small molecule platinum compound. After being passively transported into the cell through the transport channel on the surface of the cell membrane, under normal circumstances, the concentration of chloride ions in the cytoplasm is lower than that of hydrated ions, and the chloride ions are replaced by water to form hydrated cations that can interact with the nucleus. DNA bases combine to form DNA-platinum cross-link...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P35/00A61K33/243
CPCA61K31/7048A61P35/00A61K33/243A61K2300/00
Inventor 高文远满淑丽吕盼盼崔静霞
Owner TIANJIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap